Compare ESPR & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | PD |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.9M | 782.0M |
| IPO Year | 2013 | 2019 |
| Metric | ESPR | PD |
|---|---|---|
| Price | $3.19 | $10.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $8.75 | ★ $12.63 |
| AVG Volume (30 Days) | ★ 16.8M | 2.0M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.71 | ★ 416.95 |
| EPS | N/A | ★ 0.13 |
| Revenue | $403,135,000.00 | ★ $492,546,000.00 |
| Revenue This Year | N/A | $3.58 |
| Revenue Next Year | $12.81 | $2.88 |
| P/E Ratio | ★ N/A | $84.81 |
| Revenue Growth | ★ 21.31 | 5.36 |
| 52 Week Low | $1.11 | $5.70 |
| 52 Week High | $4.18 | $17.45 |
| Indicator | ESPR | PD |
|---|---|---|
| Relative Strength Index (RSI) | 67.43 | 67.72 |
| Support Level | $3.16 | $6.08 |
| Resistance Level | $3.26 | $13.43 |
| Average True Range (ATR) | 0.02 | 0.58 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 78.57 | 82.97 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.